LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
110.62
+0.14 (+0.13%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close110.48
Open110.50
Bid0.00 x 3000
Ask0.00 x 1400
Day's Range109.98 - 111.81
52 Week Range73.69 - 116.61
Volume3,884,714
Avg. Volume4,088,709
Market Cap110.344B
Beta (3Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateOct 23, 2018
Forward Dividend & Yield2.25 (2.04%)
Ex-Dividend Date2018-08-14
1y Target Est111.47
Trade prices are not sourced from all markets
  • What’s Expected for Merck’s Q3 2018 Earnings
    Market Realist11 hours ago

    What’s Expected for Merck’s Q3 2018 Earnings

    Analysts expect Merck (MRK) to report GAAP net income of $2.23 billion and GAAP EPS of $0.83 in the third quarter of 2018. In Q2 2018, the company’s GAAP net income fell YoY (year-over-year) from $1.9 billion to $1.7 billion, and its GAAP EPS fell YoY from $0.71 to $0.63. Merck’s non-GAAP net income grew ~3% YoY in Q2 2018, to $2.9 billion from $2.8 billion, and its non-GAAP EPS grew ~5% YoY from $1.01 to $1.06.

  • Lilly Declares Fourth-Quarter 2018 Dividend
    PR Newswire12 hours ago

    Lilly Declares Fourth-Quarter 2018 Dividend

    INDIANAPOLIS , Oct. 15, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2018 of $0.5625 per share on outstanding common ...

  • 3 Healthcare Stocks to Buy Amid the Carnage
    InvestorPlace14 hours ago

    3 Healthcare Stocks to Buy Amid the Carnage

    My weekend scanning revealed relative strength emanating from healthcare stocks. For the brave souls who want to continue playing, I suggest looking for relative strength to buy. Here are three healthcare stocks to buy.

  • Eli Lilly’s IPO of Animal Health Company Is Getting ‘Ahead of Itself,’ Goldman Says
    Bloomberg14 hours ago

    Eli Lilly’s IPO of Animal Health Company Is Getting ‘Ahead of Itself,’ Goldman Says

    While no analyst tracked by Bloomberg has yet rated Elanco a sell, the drugmaker for animals earned eight hold ratings, more than the five buys it received. While the company may benefit from a macro environment that includes increasing meat consumption and “humanization of pets,” Goldman Sachs analyst Jami Rubin said “the stock has gotten ahead of itself” after shares surged 36 percent through last week since a September listing at $24 per share. With the average analyst price target at $34.60, implying a return of less than 9 percent over the next twelve months, Elanco may be coming up short as investors draw comparisons to Zoetis Inc. Zoetis, the top company in medicines for pets and cattle, has seen its shares more than triple since their debut in 2013.

  • CNBC14 hours ago

    Drugmakers will soon talk about price in ads — but not as explicitly as Trump administration wants

    Some drugmakers will soon tell consumers where they can see information about drug prices. Health and Human Services Secretary Alex Azar is expected on Monday to introduce a proposal that would require drugmakers to include the list price in their direct-to-consumer advertisements. This is a key piece of President Donald Trump's blueprint to lower drug prices.

  • Novartis’ Estimates and Recommendations on October 12
    Market Realist15 hours ago

    Novartis’ Estimates and Recommendations on October 12

    Wall Street analysts estimate that Novartis (NVS) will report revenues of $13.02 billion for the third quarter of 2018, a 4.9% growth year-over-year compared to $12.41 billion. Novartis stock has decreased ~4.9% over the last 12 months. As of October 12, there are two analysts tracking Novartis ADR (American Depositary Receipts).

  • Novartis: What to Expect from Q3 Earnings on October 18
    Market Realist18 hours ago

    Novartis: What to Expect from Q3 Earnings on October 18

    Novartis (NVS) is set to release its third quarter of 2018 earnings results on October 18. Analysts are estimating EPS of $1.31 and revenues of $13.02 billion. Novartis, one of the largest pharmaceutical companies by revenue, specializes in the development, manufacturing, and marketing of healthcare products.

  • New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting
    PR Newswire19 hours ago

    New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting

    - Forty-one abstracts supporting Taltz® and Olumiant® reveal new data including findings in ankylosing spondylitis (radiographic axial spondyloarthritis), psoriatic arthritis, systemic lupus erythematosus ...

  • A Financial Overview of Bausch Health in October
    Market Realist3 days ago

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.

  • How Analysts View Bausch Health in October
    Market Realist3 days ago

    How Analysts View Bausch Health in October

    In the second quarter, Bausch Health (BHC) reported net income and diluted EPS of -$873.0 million and -$2.49, respectively, compared to -$38.0 million and -$0.11 in the second quarter of 2017. In the first half, Bausch Health generated net income and diluted EPS of -$3.45 million and -$9.84, respectively, compared to $590.0 million and $1.68 in the first half of 2017.

  • 3 Large-Cap Pharma Stocks Performing Better Than Industry
    Zacks4 days ago

    3 Large-Cap Pharma Stocks Performing Better Than Industry

    We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.

  • Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
    Zacks4 days ago

    Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?

    Is (LLY) Outperforming Other Medical Stocks This Year?

  • This is Why Eli Lilly (LLY) is a Great Dividend Stock
    Zacks4 days ago

    This is Why Eli Lilly (LLY) is a Great Dividend Stock

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

  • Lilly and Metastatic Breast Cancer Advocates Launch Thriver Movement to Elevate Understanding of the Daily Impact of the Disease, Encourage Public to do More for MBC
    PR Newswire4 days ago

    Lilly and Metastatic Breast Cancer Advocates Launch Thriver Movement to Elevate Understanding of the Daily Impact of the Disease, Encourage Public to do More for MBC

    - National survey uncovers majority of people living with MBC say the daily stress and anxiety they experience associated with the disease can impact everything from relationships to careers, with many ...

  • Investor Insights: Teva Pharmaceutical’s Valuation Multiples
    Market Realist4 days ago

    Investor Insights: Teva Pharmaceutical’s Valuation Multiples

    On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x. Its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple, a capital-structure-neutral valuation measure, is 10.4x, which is higher than the industry average of 9.4x. A company’s forward PE ratio reflects the market’s views in regards to the company’s growth potential over the next 12 months.

  • Here’s why you should expect more ‘beats’ during this earnings season
    MarketWatch5 days ago

    Here’s why you should expect more ‘beats’ during this earnings season

    It’s common for earnings ‘beats’ to be set up by companies by lowering expectations. But analysts have raised price targets for many companies too.

  • Benzinga6 days ago

    The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 9) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...

  • New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease
    PR Newswire6 days ago

    New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

    RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 10, 2018 /PRNewswire/ -- Novel results based on data from the landmark EMPA-REG OUTCOME® trial were published in the journal Circulation which suggest that treatment with Jardiance® positively impacts life expectancy in adults with type 2 diabetes and established cardiovascular disease, Boehringer Ingelheim and Eli Lilly and Company (LLY) announced today. Using actuarial methods*, and assuming that the demonstrated beneficial effects of Jardiance remain consistent with long-term use, Jardiance was estimated to extend life expectancy by 1 to 4.5 years on average, depending on age, when compared with placebo. This analysis suggests that treatment with Jardiance could add years of life.

  • CNW Group6 days ago

    Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes

    Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes

  • 4 Reasons to Be Wary of This Animal Health IPO
    Motley Fool6 days ago

    4 Reasons to Be Wary of This Animal Health IPO

    Eli Lilly's spin-off of Elanco creates a new investment opportunity in a growing market, but should you jump in?

  • A Look at Novartis’s Valuation on October 9
    Market Realist6 days ago

    A Look at Novartis’s Valuation on October 9

    Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue compared to $12.2 billion in the second quarter of 2017.

  • Assessing Novartis’s Performance in October So Far
    Market Realist7 days ago

    Assessing Novartis’s Performance in October So Far

    Novartis (NVS) is a leading pharmaceutical company specializing in the research, development, manufacturing, and marketing of a broad range of healthcare products.

  • GuruFocus.com7 days ago

    5 Companies Hit 52-Week Highs

    As of late, multiple companies have managed to reach yearly highs

  • A Walk-Through of Eli Lilly’s Alzheimer’s Disease Portfolio
    Market Realist7 days ago

    A Walk-Through of Eli Lilly’s Alzheimer’s Disease Portfolio

    In the first half, Eli Lilly reported net revenues of $12.1 billion compared to $11.1 billion in the first half of 2017. Wall Street analysts expect Eli Lilly to generate revenues of $6.1 billion in the third quarter. In the first half, Eli Lilly reported GAAP net income and earnings per share of $957.5 million and $0.92, respectively.

  • PR Newswire7 days ago

    Lilly to Present New Data From Oncology Portfolio at ESMO 2018 Congress, Showcasing Patient-Centric Advances in Cancer Care

    Data from abemaciclib, pemetrexed and ramucirumab late-stage clinical development programs in multiple difficult-to-treat tumor types New data for pegilodecakin used as a single agent and in combination ...